| Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. | |
| | |
MedLine Citation:
|
PMID: 18513146 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir. |
| | |
Authors:
|
Marian Iwamoto; Larissa A Wenning; Goutam C Mistry; Amelia S Petry; Sarah Y Liou; Kaylan Ghosh; Sheila Breidinger; Neal Azrolan; Maria J Gutierrez; William E Bridson; Julie A Stone; Keith M Gottesdiener; John A Wagner |
Related Documents
:
|
6084576 - Lymphocyte markers: diagnostic help or costly vogue? 9091066 - Purine metabolism in hiv-1 virus-infected t lymphocyte population. 16226156 - Luminous lip-prints as criminal evidence. 2182546 - Hazards of contact lenses used by workers. 16282316 - Tetrodotoxication with nassauris glans: a possibility of tetrodotoxin spreading in mari... 17154146 - Suicide notes: psychological and clinical profile. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: 47 ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-06-04 Completed Date: 2008-07-03 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 137-40 Citation Subset: IM |
Affiliation:
|
Merck, Whitehouse Station, RY34-A500, PO Box 2000, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-HIV Agents / pharmacokinetics* Double-Blind Method Female Humans Male Oligopeptides / administration & dosage, pharmacokinetics* Organic Chemicals / administration & dosage, pharmacokinetics* Placebos / administration & dosage Plasma / chemistry* Pyridines / administration & dosage, pharmacokinetics* Pyrrolidinones |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/MK 0518; 0/Oligopeptides; 0/Organic Chemicals; 0/Placebos; 0/Pyridines; 0/Pyrrolidinones; 198904-31-3/atazanavir |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008).
Next Document: Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial v...